Special article. The role of beta-adrenergic blockade in myocardial infarction.
D000284:Administration, Oral; D000311:Adrenal Glands / Q000502:physiology; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000526:Alprenolol / Q000494:pharmacology; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000009:adverse effects; D006327:Heart Block / Q000209:etiology; D006439:Hemodynamics; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality; D011217:Practolol / Q000378:metabolism / Q000494:pharmacology; D011433:Propranolol / Q000009:adverse effects / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013564:Sympathetic Nervous System / Q000502:physiology; D013566:Sympathomimetics / Q000494:pharmacology; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D001993:Bronchodilator Agents; D013566:Sympathomimetics; D000526:Alprenolol; D011433:Propranolol; D011217:Practolol